Alemtuzumab as remission induction for adult patients with acute lymphoblastic leukaemia in relapse: a randomized phase II study.
Phase of Trial: Phase II
Latest Information Update: 31 May 2016
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Acute lymphoblastic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOVON-74-ALL
- 31 May 2016 Last checked against Netherlands Trial Register record.
- 02 Apr 2009 New source identified and integrated (Netherlands Trial Register).
- 01 Oct 2006 New trial record.